Page 2 - Active Pharma News Today

/PRNewswire/ -- According to the new market research report "Pharmaceutical Contract Development and Manufacturing Market (Pharmaceutical, Biologics, Active...

Explore Now NEW DELHI: Solara Active, which has been rallying for three years now, has suddenly got its first ‘sell’ rating. As if on cue, the stock tanked 3.5 per cent in Mumbai trading on Thursday. The stock, which got listed at Rs 288 on June 27, 2018, hit a record high of Rs 1,859 on Wednesday, rising a solid 550 per cent, or 6.45 times, in less than three years. Six brokerages that cover the stock, all still have ‘buy’ ratings. But Antique Stock Broking initiated coverage on it on ...

Nifty, Sensex under pressure– Monday closing report Moneylife Digital Team  0 We had mentioned in previous week’s closing report that Nifty, Sensex were directionless. On Monday, the indices suffered a major correction and ended with huge losses. On the NSE, there were 241 advances, 1,740 declines and 313 unchanged.   The trends of the major indices in the course of Monday’s trading are given in the table below:     Tata Power Company terminated a near USD 2- billion investment deal ...

Pharmaceutical Contract Development and Manufacturing Market worth $146.1 billion by 2025 - Exclusive Report by MarketsandMarkets "Pharmaceutical Contract Development and Manufacturing Market (Pharmaceutical, Biologics, Active Pharma ingredients, tablet, Parenteral, Oral Liquid, Semi-Solids), End User (Big Pharma, Small Pharma, Generic Pharma,CRO)-Global Forecast to 2025", published by MarketsandMarkets, the global Pharmaceutical Contract Manufacturing Market is projected to reach USD 146.1 bi...

Options data suggested a wider trading range between 13,200 and 14,000/14,200 levels ahead of the Budget.